{
  "meta": {
    "timestamp": "2025-01-06T14:17:01.117273",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Vera Therapeutics Inc.",
      "symbol": "VERA",
      "analysis": {
        "historical": {
          "risk_score": 70,
          "key_risks": [
            "Clinical trial risks, particularly late-stage trial failures for Atacicept",
            "Regulatory uncertainty and potential delays or rejections from agencies like the FDA and EMA",
            "Financial sustainability and reliance on external funding",
            "Highly competitive immunology and autoimmune disease space",
            "Dependence on third-party manufacturers for drug production"
          ],
          "controversies": [
            "Shareholder litigation and investigations into claims of misleading statements regarding Phase 2b ORIGIN trial results"
          ],
          "environmental_issues": [],
          "social_issues": [],
          "governance_issues": [
            "Concerns about transparency and investor confidence due to shareholder litigation"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "C Phase 2b Clinical Trial Data Update - ir.veratx.com",
              "snippet": "Atacicept for IgA Nephropathy Self-administered subcutaneous biologic therapy in development for IgAN Targets the source of IgAN disease, Gd-IgA1 and its immune complexes, by inhibiting",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:32.804024+00:00",
              "published_date": null,
              "source_hash": "5411c14d309c94ebcc745fd55963bea9"
            },
            {
              "url": "",
              "title": "Vera Therapeutics' Atacicept Shows Sustained, Substantial ... - Benzinga",
              "snippet": "Earlier this year, Vera Therapeutics revealed 72-week data from the open-label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN).",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:32.804221+00:00",
              "published_date": null,
              "source_hash": "22a863fc5d9f644a0474b3d5bafbcb35"
            },
            {
              "url": "",
              "title": "Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement ...",
              "snippet": "On Saturday, Vera Therapeutics Inc. (NASDAQ:VERA) released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), which showed stabilized kidney function through ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:32.804263+00:00",
              "published_date": null,
              "source_hash": "c54a38b966ad99d6467621bea2b89f63"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Announces 96-week eGFR Stabilization in ... - BioSpace",
              "snippet": "BRISBANE, Calif., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:32.804277+00:00",
              "published_date": null,
              "source_hash": "fbda21fd1368c269acc13eee4d3a206f"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Announces Long-Term Kidney Function Stabilization ...",
              "snippet": "Vera Therapeutics Inc. announced results from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy or IgAN, demonstrating stabilized kidney function over 96 weeks of long-term follow-up.\"The 96-week results from the ORIGIN Phase 2b study demonstrated sustained and substantial reductions in Gd-IgA1, hematuria and proteinuria as measured by UPCR with long-term stabilization of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:32.804289+00:00",
              "published_date": null,
              "source_hash": "c88842ac32733e80321b25cfc962d706"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study ...",
              "snippet": "BRISBANE, Calif., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transfor News Today's news",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:32.804301+00:00",
              "published_date": null,
              "source_hash": "01048bb106608837e76f97e23da52393"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study ...",
              "snippet": "--Vera Therapeutics, Inc., ... to first occurrence of composite kidney failure endpoint event. ... longer term results from Vera's Phase 2b ORIGIN clinical trial and Vera's product candidates ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:32.804311+00:00",
              "published_date": null,
              "source_hash": "18c04a0dd2d13f8b2e40d692f92318d9"
            },
            {
              "url": "",
              "title": "Vera Therapeutics : Long-term Results From the ORIGIN Phase 2b Study of ...",
              "snippet": "Vera Therapeutics Inc. published this content on October 28, 2024, and is solely responsible for the information contained herein ... The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:32.804320+00:00",
              "published_date": null,
              "source_hash": "6194ba4a5207e43294442cffa3b2d6f9"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN ...",
              "snippet": "Two informational posters for ORIGIN Phase 3 and ORIGIN Extend trials of atacicept in IgAN accepted for presentation at Kidney Week;In-person and virtual R&D Day to discuss expanded atacicept R&D ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:32.804331+00:00",
              "published_date": null,
              "source_hash": "eda66334b854f00841cca40d0bcf6afe"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Announces Late-Breaking Oral ... - Morningstar",
              "snippet": "Vera believes atacicept is positioned for best-in-class potential, targeting B cells and plasma cells to reduce autoantibodies and having been administered to more than 1,500 patients in clinical ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:32.804340+00:00",
              "published_date": null,
              "source_hash": "5c4d1855458ca10d7736972e36c3e243"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. Class A",
              "snippet": "Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:35.264097+00:00",
              "published_date": "2024-01-03T22:34:00+00:00",
              "source_hash": "f63b2caa700ef5e8ccca38a40c4fa4ff"
            },
            {
              "url": "",
              "title": "10 clinical trials to watch in the first half of 2025",
              "snippet": "Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology sector regain its footing after a shaky year.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:35.264176+00:00",
              "published_date": "2025-01-02T11:49:00+00:00",
              "source_hash": "fd19fe4d1f997c1f70c306cee422dec4"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Wellington Management Group LLP",
              "snippet": "Wellington Management Group LLP trimmed its position in shares of Vera Therapeutics, Inc. (NASDAQ ... injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:45.374207+00:00",
              "published_date": "2024-12-20T00:00:00+00:00",
              "source_hash": "86a7e7b3c4736960f941bdf1373b604d"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Fmr LLC",
              "snippet": "Fmr LLC lessened its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report ... a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:35.264200+00:00",
              "published_date": "2024-12-05T00:00:00+00:00",
              "source_hash": "7c5e10a5d7610ab3d86561960056e762"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
              "snippet": "Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA ... Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:16:35.264210+00:00",
              "published_date": "2024-12-09T15:30:00+00:00",
              "source_hash": "6e2274a1a4fd1137f440620440a15fbf"
            },
            {
              "url": "",
              "title": "Vera Therapeutics (VERA) 10K Form and SEC Filings 2025 - MarketBeat",
              "snippet": "03/21/2024 3:54 PM: Katabi Maha (Reporting) Vera Therapeutics (Subject) Form 144 Notice of proposed sale of securities pursuant to Rule 144 : 03/20/2024 6:30 AM: Vera Therapeutics (Filer) Form 8-K Current report pursuant to Section 13 or 15(d) : 02/20/2024 6:11 PM: Sofinnova Venture Partners X, L.P. (Filed by) Vera Therapeutics (Subject) Form SC 13D/A",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:36.727234+00:00",
              "published_date": null,
              "source_hash": "bd7c43a017f04b7a8490a232a538ae78"
            },
            {
              "url": "",
              "title": "VERA / Vera Therapeutics, Inc. - SEC Filings, Annual Report ... - Fintel",
              "snippet": "Vera Therapeutics, Inc. 8000 Marina Boulevard, Suite 120 Brisbane, CA 94005 (650) 770-0077 June 9, 2022 VIA EDGAR Michael Davis United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Vera Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-265408) Request for ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:36.727337+00:00",
              "published_date": null,
              "source_hash": "0b7a05ca74b0d47af47fd18950d6b803"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. - AnnualReports.com",
              "snippet": "Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. ... Vera's lead product candidate is atacicept, a fusion protein self ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:36.727350+00:00",
              "published_date": null,
              "source_hash": "73d293d4ccfe80f846801177f6142d04"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. (VERA) 10K Annual Reports & 10Q SEC Filings",
              "snippet": "Inside Vera Therapeutics, Inc.'s 10-K Annual Report: Financial - Cash Flow Highlight. However, should adverse geopolitical and macroeconomic events, such as ongoing military conflicts, related sanctions, any recession or depression associated with those events or other events described herein, continue for a prolonged period, our results of operations, financial condition, liquidity and cash ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:36.727360+00:00",
              "published_date": null,
              "source_hash": "58fa11ffe86495658c860447bb8e7680"
            },
            {
              "url": "",
              "title": "8-K - SEC.gov",
              "snippet": "On March 28, 2023, Vera Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:36.727371+00:00",
              "published_date": null,
              "source_hash": "c39b16432766916958d0eed887886e8e"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Inc. - Filings and Transcripts - BamSEC",
              "snippet": "SEC filings and transcripts for Vera Therapeutics Inc., including financials, news, proxies, indentures, prospectuses, and credit agreements ... NASDAQ: VERA Share price (12/30/24): $42.06 Market cap (12/30/24): $2.663 billion Categorized Chronological ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:36.727380+00:00",
              "published_date": null,
              "source_hash": "2e8e389fa5a156bce681b79b6ed3b175"
            },
            {
              "url": "",
              "title": "VERA SEC Filings - Vera Therapeutics, Inc.- Annual Report, Proxy ...",
              "snippet": "Exhibit 10.11 Vera Therapeutics, Inc. Non-Employee Director Compensation Policy Amended and Restated Effective January 1, 2024 Each member of the Board of Directors (the \"Board\") of Vera Therapeutics, Inc. (the \"Company\") who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an \"Eligible ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:36.727391+00:00",
              "published_date": null,
              "source_hash": "997ccc5674db207dc112c599d8b586b4"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. SEC 10-Q Report \u2014 TradingView News",
              "snippet": "Vera Therapeutics, Inc., a biotechnology company focused on developing treatments for immunologic and kidney diseases, has released its latest Form 10-Q report. The report provides a comprehensive overview of the company's financial performance, business operations, strategic initiatives, and the c\u2026",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:36.727401+00:00",
              "published_date": null,
              "source_hash": "9010ca67e6367b6df4efc0a8f9449e42"
            },
            {
              "url": "",
              "title": "Vera Therapeutics NasdaqGM:VERA Stock Report - Simply Wall St",
              "snippet": "Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.000036 million. ... Data is normalised which can introduce a delay from the source being available. Package Data Timeframe Example US Source * Company Financials: ... for non-US equivalent regulatory forms and sources are used.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:36.727415+00:00",
              "published_date": null,
              "source_hash": "746a6a15e685de5dbded3c83f4fe4954"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Provides Business Update and Reports Second Quarter ...",
              "snippet": "BRISBANE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:36.727425+00:00",
              "published_date": null,
              "source_hash": "f790624ff2e4cb0527195ed84959f370"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Barclays PLC",
              "snippet": "Barclays PLC increased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 94.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:45.374111+00:00",
              "published_date": "2024-12-23T07:55:00+00:00",
              "source_hash": "af60b5bb002a13f26a00c7d6868037da"
            },
            {
              "url": "",
              "title": "Brokerages Set Vera Therapeutics, Inc. (NASDAQ:VERA) Target Price at $63.50",
              "snippet": "Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have earned a consensus recommendation of \"Buy\" from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:40.466093+00:00",
              "published_date": "2024-12-30T05:54:00+00:00",
              "source_hash": "956a25575248e78a4af4456b6adc5e7c"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. (VERA)",
              "snippet": "Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA ... potential of BAFF/APRIL dual inhibition;Multiple regulatory and clinical milestones expected over the next 18 months ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:40.466106+00:00",
              "published_date": "2024-12-20T00:00:00+00:00",
              "source_hash": "0c334f770e2ed5d35b03e5fc15cc23a1"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Wellington Management Group LLP",
              "snippet": "Vera Therapeutics, Inc. has a fifty-two week low of $14.20 and a fifty-two week high of $51.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:40.466116+00:00",
              "published_date": "2024-12-20T00:00:00+00:00",
              "source_hash": "b7f57ca22c672d5ec5de370f6bece93b"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
              "snippet": "BRISBANE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 171,750 shares ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. regulatory rejections or delays",
              "retrieved_at": "2025-01-06T21:16:40.466125+00:00",
              "published_date": "2024-12-12T00:00:00+00:00",
              "source_hash": "f10beebdf4fe0f75e9427d5019526ae0"
            },
            {
              "url": "",
              "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of ...",
              "snippet": "NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. (\"Vera\" or the \"Company\") (NASDAQ: VERA).Such investors are advised ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:42.873669+00:00",
              "published_date": null,
              "source_hash": "d1ff387246e3ca350c9009e2c45b02a0"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC",
              "snippet": "Home \\ Vera Therapeutics, Inc. ... Vera issued a press release announcing what it characterized as \"positive topline results\" in its Phase 2b ORIGIN clinical trial of atacicept for the treatment of immunoglobulin A nephropathy. Although Vera's product candidate met its primary endpoint, analysts noted that the Phase 2b data would need to ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:42.873777+00:00",
              "published_date": null,
              "source_hash": "49c03619c490381fc5bcffaf8666f5fe"
            },
            {
              "url": "",
              "title": "Vera Therapeutics (VERA) Stock Price, News & Analysis - MarketBeat",
              "snippet": "Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:42.873792+00:00",
              "published_date": null,
              "source_hash": "6896148452407dc579cbfe7b2d5ad612"
            },
            {
              "url": "",
              "title": "Vera Therapeutics at the Crossroads Exciting Clinical Progress Amidst ...",
              "snippet": "Navigating Clinical Progress and Market Challenges: Vera Therapeutics? ORIGIN Phase 2b Trial Results at ASN Kidney Week 2024 Vera Therapeutics recently announced a late-breaking oral presentation of the long-term results from their ORIGIN Phase 2b clinical trial at the prestigious American Society of Nephrology (ASN) Kidney Week 2024. This development marks a significant milestone in the ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:42.873803+00:00",
              "published_date": null,
              "source_hash": "8dbe7d28fc7b291294838a1a980a7409"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. (VERA) stock price, news, quote and history ...",
              "snippet": "It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. veratx.com",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:42.873813+00:00",
              "published_date": null,
              "source_hash": "40df230f3d1efb15519c54e419b891b8"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. (VERA) Company Profile & Overview - Stock Analysis",
              "snippet": "Company profile for Vera Therapeutics, Inc. (VERA) with a description, list of executives, contact details and other key facts. ... and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:42.873823+00:00",
              "published_date": null,
              "source_hash": "530b3568e6a03d4098a3b289e49f3262"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. (VERA) Stock Price, Quote & News - Stock Analysis",
              "snippet": "Get a real-time Vera Therapeutics, Inc. (VERA) stock price quote with breaking news, financials, statistics, charts and more. ... and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was for...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:42.873832+00:00",
              "published_date": null,
              "source_hash": "68b7eb2c592fcab094dc06445fe6e779"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Inc (VERA) Reports Q3 Financial Results and Business ...",
              "snippet": "On November 9, 2023, Vera Therapeutics Inc (NASDAQ:VERA), a late clinical-stage biotechnology company, released its third-quarter financial results and provided a business update. The company ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:42.873842+00:00",
              "published_date": null,
              "source_hash": "7495fcd1ed6097eddb02195ed3b50c86"
            },
            {
              "url": "",
              "title": "Promising Clinical Data and Strong Financials Justify Buy Rating for ...",
              "snippet": "Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:42.873850+00:00",
              "published_date": null,
              "source_hash": "eda10676fe5dd3fde9a98fb5423fb234"
            },
            {
              "url": "",
              "title": "New lawsuit details why Denali Therapeutics backed out of its Industry ...",
              "snippet": "Denali Therapeutics' new Salt Lake City lab was supposed to be part of the city's biotech \"boost.\" A new lawsuit, filed by Denali against the owners of the INDUSTRY SLC building, details why it ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:42.873859+00:00",
              "published_date": null,
              "source_hash": "30474b8817634d7ae9efe8756fa999ac"
            },
            {
              "url": "",
              "title": "Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet",
              "snippet": "Shares of Vera Therapeutics, Inc. (VERA) have gained 12.6% over the past four weeks to close the last trading session at $48.09, but there could still be a solid upside left in the stock if short ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:45.374195+00:00",
              "published_date": "2024-11-11T16:34:00+00:00",
              "source_hash": "8339d9c3b3e1d73223026c45bb34acb5"
            },
            {
              "url": "",
              "title": "Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
              "snippet": "BRISBANE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:45.374218+00:00",
              "published_date": "2024-12-09T15:30:00+00:00",
              "source_hash": "e4ffdc0ae1307d76fcdf7f4a22bca29e"
            },
            {
              "url": "",
              "title": "Vera Therapeutics, Inc. (VERA)",
              "snippet": "Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biot Two informational posters for ORIGIN Phase 3 and ORIGIN Extend trials of atacicept in IgAN accepted for presentation at Kidney ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Vera Therapeutics Inc. Vera Therapeutics Inc. controversies in clinical trial practices",
              "retrieved_at": "2025-01-06T21:16:45.374228+00:00",
              "published_date": "2024-12-20T00:00:00+00:00",
              "source_hash": "e086421dde24a3bf4b2e4226ffc43645"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Vera Therapeutics Inc. clinical trial failures or delays",
              "rationale": "Investigate potential risks related to the success of ongoing clinical trials, which could impact the company's financial stability and regulatory approvals.",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Vera Therapeutics Inc. regulatory rejections or delays",
              "rationale": "Examine any instances of regulatory setbacks or delays with the FDA or EMA, which could hinder the commercialization of Atacicept or other pipeline candidates.",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Vera Therapeutics Inc. controversies in clinical trial practices",
              "rationale": "Assess whether there have been any ethical concerns or controversies related to the company's clinical trial conduct, such as patient safety issues or transparency in reporting results.",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:17:01.117280",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}